Evidence-Based Management of Advanced Gastric Cancer:
Current and Emerging Targeted Therapies
Release Date: August 14, 2014
Last Reviewed: July 11, 2014    
Expiration Date: August 14, 2015
Time to Complete:  1.0 hour

*This activity expired for credit on August 14, 2015 and is no longer available for credit
This activity is provided by Global Education Group. 
Paradigm Medical Communications, LLC is the educational partner.
Manish A. Shah, MD
Associate Professor of Medicine
Director, Gastrointestinal Oncology
Weill Cornell Medical College
Associate Attending Physician
Director, Research
Center of Advanced Digestive Care
New York–Presbyterian Hospital
New York, NY
Peter C. Enzinger, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Center for Esophageal and Gastric Cancer
Dana–Farber Cancer Institute
Boston, MA
Target Audience
This educational initiative is designed to meet the needs of medical oncologists, surgical oncologists, interventional radiologists, gastroenterologists/endoscopy specialists, colon and rectal surgeons, general surgeons, pathologists, oncology nurses, nurse practitioners, physician assistants, and other healthcare professionalsinvolved in the management of advanced gastric cancer.
Statement of Need
Gastric cancer is the 2nd leading cause of cancer mortality and the 4th most common malignancy worldwide. An estimated 21,600 new cases of gastric cancer will be diagnosed in the US in 2013, and more than 10,000 people will die of the disease. Although treatment of resectable gastric cancer has improved over the last 2 decades, historically, little progress has been made in advanced gastric cancer. That is beginning to change with the FDA approval of a targeted second-line treatment for metastatic gastric cancer in April 2014, and the ongoing investigation of other promising agents targeting aberrant signaling pathways. These new treatments have the potential to substantially improve patient outcomes. However, with each new treatment, clinicians must stay abreast of the underlying mechanisms, current data, and treatment-emergent adverse events to provide their patients with optimal care. The amount of information surrounding emerging treatments for gastric cancer can be daunting; this monograph will provide clinicians with a much-needed, concise overview of the available data.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Describe aberrant signaling pathways and potential actionable targets in advanced gastric cancer.
  • Discuss recent clinical trial data on current and emerging targeted therapies for advanced gastric cancer.
  • Identify adverse events associated with targeted therapies when used alone or in combination with other treatments.


  • Introduction
  • First-Line Treatment for Advanced Gastric Cancer
  • Second-Line Treatment for Advanced Gastric Cancer
  • Emerging Targeted Therapies for Advanced Gastric Cancer
  • Conclusion
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation Statement
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1 hour of Category 1 credit for completing this program.
Nurse Continuing Education
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 1101021.
This program has been approved for 1.0 contact hours of continuing education (which includes .50 hours of pharmacology).
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.
Disclosure of Commercial Support
This activity is supported by an independent educational grant from Lilly, USA LLC.
Instructions for Participation
To receive a certificate of participation, participants should:
  • Follow instructions to register or log in with your professional information and complete the
  • pretest.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the activity.
  • A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
There is no fee required for participation in this activity.
Hardware/Software Requirements
This certified CME activity includes HTML5 video interspersed throughout. When you encounter a video highlight, click the ‘play’ button in order to begin viewing the video highlight.
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Name of Faculty or Presenter
Reported Financial Relationship
Manish A. Shah, MD
Grant/Research Support:Sanofi-Aventis US LLC.
Peter C. Enzinger, MD
Retained Consultant:Taiho Pharmaceutical Co., Ltd
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager
Reported Financial Relationship
Ashley Marostica, RN, MSN
Nothing to disclose
Amanda Glazar, PhD
Nothing to disclose
Amanda Hodges
Nothing to disclose
Paradigm Medical Communications, LLC staff members have no financial conflicts to disclose.
Independent peer reviewer has no financial conflicts to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC and Global Education Group have implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC or Global Education Group. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC or Global Education Group. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm or Global. Paradigm and Global accept no liability for the content referenced in this activity.
Privacy policy
Paradigm and Global arecommitted to protecting the privacy of those who participate in the activities (herein referred to as "website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm and Global to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please emailus at contactus@paradigmmc.com.
© 2014 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.